A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms

被引：1

作者：

Rivera-Concepcion, Joel ^{[1
]}

Lo, Ying-Chun ^{[2
]}

Uprety, Dipesh ^{[3
]}

Adjei, Alex A. ^{[4
]}

Ernani, Vinicius ^{[5
]}

Leventakos, Konstantinos ^{[6
]}

机构：

[1] Duke Canc Inst, Dept Med Oncol, 20 Duke Med Circle, Durham, NC 27710 USA

[2] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA

[3] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Med Oncol, 4100 John R St, Detroit, MI 48201 USA

[4] Cleveland Clin, Taussig Canc Inst, 10201 Carnegie Ave, Cleveland, OH 44106 USA

[5] Mayo Clin, Div Med Oncol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA

[6] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA

来源：

CURRENT PROBLEMS IN CANCER: CASE REPORTS | 2024年 / 13卷

关键词：

NSCLC; EGFR mutation; Histologic transformation; Acquired resistance; Neuroendocrine cancer; CELL NEUROENDOCRINE CARCINOMA; GEFITINIB PLUS CHEMOTHERAPY; ACQUIRED-RESISTANCE; OSIMERTINIB; PROGRESSION; SURVIVAL; T790M;

D O I：

10.1016/j.cpccr.2024.100284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This clinical case presents a patient with NSCLC who experienced on-target resistant mutations and tumor cell transformation from adenocarcinoma to large cell neuroendocrine and small cell carcinoma. Our patient was successfully treated with a combination of targeted therapy, immunotherapy and chemotherapy based on genetic and histologic changes that occurred in a period of five years.

引用

页数：4

共 19 条

[1] Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
Di Noia, V.
D'Aveni, A.
D'Argento, E.
Rossi, S.
Ghirardelli, P.
Bortolotti, L. .
Vavassori, V.
Bria, E.
Ceresoli, G. L.
[J]. ESMO OPEN, 2021, 6 (06)
[2] Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations
Ding, Ting
Zhou, Fei
Chen, Xiaoxia
Zhang, Shijia
Liu, Yinan
Sun, Hui
Ren, Shengxiang
Li, Xuefei
Zhao, Chao
Wang, Heyong
Zhou, Caicun
[J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2923 - +
[3] Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Goldberg, Sarah B.
Oxnard, Geoffrey R.
Digumarthy, Subba
Muzikansky, Alona
Jackman, David M.
Lennes, Inga T.
Sequist, Lecia V.
[J]. ONCOLOGIST, 2013, 18 (11) : 1214 - 1220
[4] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Horn, L.
Mansfield, A. S.
Szczesna, A.
Havel, L.
Krzakowski, M.
Hochmair, M. J.
Huemer, F.
Losonczy, G.
Johnson, M. L.
Nishio, M.
Reck, M.
Mok, T.
Lam, S.
Shames, D. S.
Liu, J.
Ding, B.
Lopez-Chavez, A.
Kabbinavar, F.
Lin, W.
Sandler, A.
Liu, S. V.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) : 2220 - 2229
[5] Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor
Kogo, Mariko
Shimizu, Ryoko
Uehara, Keiichiro
Takahashi, Yutaka
Kokubo, Masaki
Imai, Yukihiro
Tomii, Keisuke
[J]. LUNG CANCER, 2015, 90 (02) : 364 - 368
[6] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
Mok, T. S.
Wu, Y. -L.
Ahn, M. -J.
Garassino, M. C.
Kim, H. R.
Ramalingam, S. S.
Shepherd, F. A.
He, Y.
Akamatsu, H.
Theelen, W. S. M. E.
Lee, C. K.
Sebastian, M.
Templeton, A.
Mann, H.
Marotti, M.
Ghiorghiu, S.
Papadimitrakopoulou, V. A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) : 629 - 640
[7] Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
Mok, Tony S. K.
Kim, Sang-We
Wu, Yi-Long
Nakagawa, Kazuhiko
Yang, Jin-Ji
Ahn, Myung-Ju
Wang, Jie
Yang, James Chih-Hsin
Lu, You
Atagi, Shinji
Ponce, Santiago
Shi, Xiaojin
Rukazenkov, Yuri
Haddad, Vincent
Thress, Kenneth S.
Soria, Jean-Charles
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4027 - +
[8] RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, Matthew J.
Sequist, Lecia V.
Poirier, John T.
Mermel, Craig H.
Lockerman, Elizabeth L.
Garcia, Angel R.
Katayama, Ryohei
Costa, Carlotta
Ross, Kenneth N.
Moran, Teresa
Howe, Emily
Fulton, Linnea E.
Mulvey, Hillary E.
Bernardo, Lindsay A.
Mohamoud, Farhiya
Miyoshi, Norikatsu
VanderLaan, Paul A.
Costa, Daniel B.
Jaenne, Pasi A.
Borger, Darrell R.
Ramaswamy, Sridhar
Shioda, Toshi
Iafrate, Anthony J.
Getz, Gad
Rudin, Charles M.
Mino-Kenudson, Mari
Engelman, Jeffrey A.
[J]. NATURE COMMUNICATIONS, 2015, 6
[9] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, Luis
Dvorkin, Mikhail
Chen, Yuanbin
Reinmuth, Niels
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Ji, Jun Ho
Voitko, Oleksandr
Poltoratskiy, Artem
Ponce, Santiago
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Kazarnowicz, Andrzej
Losonczy, Gyorgy
Conev, Nikolay V.
Armstrong, Jon
Byrne, Natalie
Shire, Norah
Jiang, Haiyi
Goldman, Jonathan W.
Batagelj, Emilio
Casarini, Ignacio
Pastor, Anea Viviana
Sena, Susana Noemi
Zarba, Juan Jose
Burghuber, Otto
Hartl, Sylvia
Hochmair, Maximilian J.
Lamprecht, Bernd
Studnicka, Michael
Schlittler, Luis Alberto
de Oliveira, Fabricio Augusto Martinelli
Calabrich, Aknar
Girotto, Gustavo Colagiovanni
Dos Reis, Peo
Gorini, Carlos Fausto Nino
De Marchi, Peo Rafael Martins
Baldotto, Clarissa Serodio da Rocha
Sette, Claudia
Zukin, Mauro
Conev, Nikolay V.
Dudov, Assen
Ilieva, Rumyana
Koynov, Krassimir
Krasteva, Rositsa
Tonev, Ivan
[J]. LANCET, 2019, 394 (10212) : 1929 - 1939
[10] Quintanal-Villalonga A, 2020, NAT REV CLIN ONCOL, V17, P360, DOI 10.1038/s41571-020-0340-z

← 1 2 →